title: [Predictive and prognostic value of monitoring lymphocyte subsets in peripheral blood before and after chemotherapy in patients with metastatic breast cancer].
abstract: OBJECTIVE
  To detect the proportion of lymphocyte subsets in peripheral blood of the advanced breast cancer patients before and after chemotherapy with docetaxel and thiotepa, as well as the association between the proportion of peripheral blood lymphocyte subsets with the response rate and prognosis.
  
  
  METHODS
  The proportions of lymphocyte subsets (CD3+ T cell, CD3+/CD4+ T cell, CD3+/CD8+ T cell, CD3-/CD16+56+ NK cell, CD3+/CD16+56+ T cell, CD19+ B cell, CD4+/CD25+ T cell, CD8+/CD28- T cell, CD8+/CD28+ T cell) in the peripheral blood of 86 patients were analyzed with flowcytometry before and after chemotherapy. The result was analyzed in combination with clinicopathological data.
  
  
  RESULTS
  The proportion of regulatory T cells (Treg) after chemotherapy in the disease control patients decreased significantly compared with that of the progressive patients (P=0.034). The difference of the proportions of Treg before and after chemotherapy affected significantly the overall survival (OS). The OS of the patients with decreased proportion of Treg was significantly longer than that of the patients with increased proportion of Treg, which was 23.5 and 9.4 months respectively (P<0.05).
  
  
  CONCLUSIONS
  The patients with decreased proportion of Treg after chemotherapy had higher response rate and better survival benefit.
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: B
authors.initials: B
authors.lastname: Shao
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: H P
authors.initials: HP
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: L J
authors.initials: LJ
authors.lastname: DI
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: G H
authors.initials: GH
authors.lastname: Song
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: H F
authors.initials: HF
authors.lastname: Jiang
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: X
authors.initials: X
authors.lastname: Liang
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: C Y
authors.initials: CY
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Yan
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: X L
authors.initials: XL
authors.lastname: Lin
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: L N
authors.initials: LN
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: F L
authors.initials: FL
authors.lastname: Wan
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: Y H
authors.initials: YH
authors.lastname: Yuan
authors.affiliation: Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, China.
authors.forename: M N
authors.initials: MN
authors.lastname: You
mesh_terms: D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D000077143:Docetaxel; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D018655:Lymphocyte Count; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000276:immunology; D011379:Prognosis; D015996:Survival Rate; D016176:T-Lymphocyte Subsets / Q000166:cytology*; D050378:T-Lymphocytes, Regulatory / Q000166:cytology*; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D043823:Taxoids; D000077143:Docetaxel